Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:PONY
NasdaqGS:PONYSoftware

Is It Time To Reassess Pony AI (PONY) After The Recent 30 Day Share Price Slump?

Wondering whether Pony AI at US$9.56 is starting to look interesting or still too expensive for the risk you would be taking. The stock has returned 3.7% over the last 7 days, while the 30 day return is a 25.9% decline and the year to date return is a 40.5% decline, set against an 80.4% return over the last year. Recent coverage has focused on Pony AI as a high growth, higher risk software name, with investors debating whether the sharp pullback in the last month is a pause after a strong 1...
TSX:CM
TSX:CMBanks

Is Canadian Imperial Bank of Commerce (TSX:CM) Still Attractive After Its Strong 1-Year Share Price Run?

If you have been wondering whether Canadian Imperial Bank of Commerce is still reasonably priced after a strong run, this article explains what the current share price could mean for long term value. The stock last closed at $142.66, with returns of 6.5% over 7 days, 6.0% over 30 days, 13.0% year to date and 86.4% over 1 year. Longer term figures of 183.6% over 3 years and 190.7% over 5 years help to frame how the market has treated the shares. Recent headlines around Canadian Imperial Bank...
NYSE:GMED
NYSE:GMEDMedical Equipment

Will Analyst Upgrades and Earnings Revisions Change Globus Medical's (GMED) Narrative?

Earlier in April 2026, Globus Medical was upgraded to a Zacks Rank #1 (Strong Buy) after analysts raised earnings estimates and signaled greater confidence in its outlook. This shift in analyst sentiment highlights how upward earnings revisions can materially influence perceptions of Globus Medical’s business quality and earnings power. Next, we’ll explore how this earnings-driven upgrade interacts with the existing investment narrative built around robotics innovation and acquisition...
TSE:8908
TSE:8908Real Estate

Mainichi Comnet (TSE:8908) Q3 EPS Strength Reinforces Bullish Earnings Growth Narrative

Mainichi Comnet (TSE:8908) has released its Q3 2026 numbers, reporting revenue of ¥9.4b, basic EPS of ¥21.22 and net income of ¥373m for the quarter. The company’s revenue increased from ¥5.3b in Q3 2025 to ¥9.4b in Q3 2026, while basic EPS rose from ¥12.65 to ¥21.22 over the same period. This provides a clearer view of how the top and bottom lines correspond to the latest 7.1% net margin profile reported for the past year. See our full analysis for Mainichi Comnet. With the headline figures...
SGX:O39
SGX:O39Banks

Is It Too Late To Consider Oversea-Chinese Banking (SGX:O39) After Its Strong Multi‑Year Rally?

If you are wondering whether Oversea-Chinese Banking is still fairly priced after its recent run, the next sections will focus squarely on what the current share price may or may not reflect. The stock last closed at S$22.47, with returns of 0.4% over 7 days, 8.3% over 30 days, 13.2% year to date, 58.9% over 1 year, 110.3% over 3 years, and 144.6% over 5 years, which puts recent price moves front and center for any valuation discussion. Investors have been paying closer attention to...
NasdaqGS:IMVT
NasdaqGS:IMVTBiotechs

Should Batoclimab’s Phase 3 Miss in Thyroid Eye Disease Require Action From Immunovant (IMVT) Investors?

In April 2026, Immunovant reported that two Phase 3 GO studies of its FcRn inhibitor batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the pre-specified primary endpoint of ≥2mm proptosis response at Week 24, though safety findings remained consistent and no new signals emerged. The data suggested stronger proptosis improvements during the initial high-dose period and thyroid hormone normalization in hyperthyroid patients similar to prior Graves’ disease...
NYSE:APD
NYSE:APDChemicals

How Investors Are Reacting To Air Products (APD) Earnings Beat, Upgraded Outlook, And Institutional Buying

In recent days, Air Products and Chemicals reported quarterly results that exceeded analyst expectations and issued more optimistic full-year guidance, alongside increased holdings by several institutional investors. This combination of stronger earnings, upbeat outlook, and active institutional accumulation highlights growing confidence in the company’s execution across its core industrial gases and clean energy projects. Building on these earnings surprises and analyst upgrades, we’ll now...
NasdaqGS:COIN
NasdaqGS:COINCapital Markets

Assessing Coinbase (COIN) Valuation After Analyst Downgrades And Concerns On Fees And Trading Volumes

Fresh attention on Coinbase Global (COIN) has been sparked by a wave of analyst coverage that questions the resilience of its fee model, trading volumes, and role in an increasingly institutional crypto market. See our latest analysis for Coinbase Global. At a share price of $167.85, Coinbase’s recent momentum has cooled, with a 30 day share price return of 15.5% lower and a 90 day return of 30.29% lower. However, the 3 year total shareholder return of 140.09% still indicates a very strong...
NYSE:KMPR
NYSE:KMPRInsurance

Is It Time To Reconsider Kemper (KMPR) After A 43.7% One Year Share Price Fall

If you are wondering whether Kemper's current share price offers fair value or a potential discount, a good starting point is understanding how the market is pricing its risks and prospects today. The stock last closed at US$31.13, with returns of 1.7% over 7 days and 6.9% over 30 days, set against a 21.2% decline year to date and a 43.7% decline over 1 year. These moves sit against a backdrop of ongoing investor focus on Kemper's position within the insurance sector and on how its business...
TSX:ELD
TSX:ELDMetals and Mining

Assessing Eldorado Gold (TSX:ELD) Valuation As Long Term Momentum Meets Recent Share Price Cooling

Eldorado Gold (TSX:ELD) is back on investors’ radar after recent share price swings, with the stock moving higher over the past day but showing declines over the month and past 3 months. See our latest analysis for Eldorado Gold. Looking beyond the latest move to CA$50.45, Eldorado Gold’s 1 day share price return of 2.37% and 7 day gain of 1.14% sit against a softer 30 day share price return of a 9.08% decline and a 90 day decline of 5.36%. The year to date share price return of 3.74%...
NasdaqGS:COO
NasdaqGS:COOMedical Equipment

A Look At Cooper Companies (COO) Valuation After Launch Of Its Global Sustainability Platform

Cooper Companies (COO) is drawing attention after its CooperVision unit launched the MADE BETTER Promise, a global sustainability platform initially tied to the MyDay daily disposable contact lens family. See our latest analysis for Cooper Companies. The share price is currently at US$71.21, with a 1-day share price return of a 0.35% decline and a 90-day share price return of a 14.67% decline. The 1-year total shareholder return of an 8.07% decline and 5-year total shareholder return of a...
NYSE:CRM
NYSE:CRMSoftware

Does Salesforce (CRM) Turning Deeper into AI Workflows Signal Durable Moat or Rising Platform Risk?

In early April 2026, Salesforce filed a shelf registration for US$41.18 million of common stock linked to its employee stock ownership plan, while partners such as Solutions by Text and Redpanda expanded integrations that deepen Salesforce’s role at the center of compliant messaging and data streaming workflows. At the same time, investors are wrestling with whether Salesforce’s AI initiatives, like Agentforce and Slackbot, will offset competitive, pricing, and workflow-disruption risks that...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

Can onsemi’s (ON) Sineng Design Win Quietly Redefine Its Edge in Utility-Scale Renewables?

On 31 March 2026, Sineng Electric announced it will use onsemi’s latest-generation FS7 IGBT and EliteSiC hybrid power integrated modules in its 430 kW liquid-cooled energy storage systems and 320 kW utility-scale solar string inverters, targeting higher efficiency, power density and improved thermal performance in utility-scale renewable installations. Benchmark data suggest onsemi’s hybrid PIMs can lift inverter system efficiency by up to 0.1% and power-to-weight performance by 32%,...
NYSE:CMG
NYSE:CMGHospitality

Has The Chipotle Mexican Grill (CMG) Pullback Brought The Share Price Closer To Fair Value

Some investors may be wondering whether Chipotle Mexican Grill is starting to look attractively priced, or if the stock still has more heat baked into it than the fundamentals support. The share price closed at US$34.09, with recent returns of 2.8% over 7 days and 0.7% over 30 days, while the year-to-date move sits at a 9.1% decline and the 1-year return at a 31.5% decline, which may have some investors reassessing both risk and potential reward. Recent coverage has focused on how this...
NYSE:EL
NYSE:ELPersonal Products

Estée Lauder Governance Scrutiny And Insider Moves Shape Merger Uncertainty

Law firm opens investigation into potential fiduciary breaches by directors and officers of Estée Lauder Companies (NYSE:EL). Review focuses on whether management acted in the best interests of shareholders during recent corporate actions. Aerin Lauder and Ronald S. Lauder transfer large blocks of Class B shares into RSL Shares Trust, now a 10% beneficial owner. These developments occur while Estée Lauder is engaged in merger negotiations with Puig. Estée Lauder Companies, the beauty group...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy?

On 9 April 2026, Tempus AI, Inc. announced an expanded multi-year collaboration giving Gilead Sciences enterprise-wide access to its AI-driven Lens platform and broader multimodal oncology datasets, alongside integrated Tempus analytical services. This deepened data and platform access positions Tempus more firmly inside Gilead’s oncology R&D workflows, embedding its technology in trial design, biomarker strategy, and real-world evidence generation across multiple cancer programs. We’ll now...
NYSE:DD
NYSE:DDChemicals

DuPont Expands Water Solutions Role With New Industrial Treatment Technologies

DuPont de Nemours (NYSE:DD) has introduced new water treatment technologies focused on industrial and municipal applications. The launch includes ultrafiltration modules with integrated pre filters and advanced reverse osmosis membrane elements. The products target resource recovery, regulatory compliance, operational efficiency and support for zero liquid discharge systems. For DuPont, water technologies sit alongside a broader portfolio that serves industrial, infrastructure and municipal...
TSE:8185
TSE:8185Specialty Retail

Chiyoda (TSE:8185) Margin Compression To 0.3% Questions Bullish Earnings Narratives

Chiyoda (TSE:8185) closed out FY 2026 with fourth quarter revenue of ¥19.3b and a basic EPS loss of ¥40.88, capping off a year in which trailing 12 month EPS stood at ¥6.89 on revenue of ¥81.4b. Over the past six quarters, revenue has moved in a tight band between ¥19.2b and ¥22.0b per quarter. Quarterly EPS has swung from a profit of ¥37.15 to a loss of ¥40.88 as net income shifted between profits of up to ¥1.31b and losses of up to ¥1.39b. That mix of steady top line and choppy earnings...
TSX:SU
TSX:SUOil and Gas

Assessing Suncor Energy (TSX:SU) Valuation After C$23b Capital Return And Operational Improvements

Suncor Energy (TSX:SU) used its 2026 Investor Day to outline plans to return more than C$23b to shareholders through dividends and buybacks, alongside highlighting reduced safety incidents and higher asset utilization. See our latest analysis for Suncor Energy. The share price has moved around in the short term, with a 1 day share price return of 1.87% and a 7 day share price return of a 2.65% decline. However, the 30 day and 90 day share price returns of 12.88% and 37.37% point to solid...
NasdaqGS:KNSA
NasdaqGS:KNSABiotechs

A Look At Kiniksa Pharmaceuticals (KNSA) Valuation As Heart’s Home Campaign Targets ARCALYST Growth

Kiniksa Pharmaceuticals International (KNSA) is in focus after launching Heart’s Home, a multi-channel Direct-to-Consumer campaign for ARCALYST, its FDA-approved therapy for recurrent pericarditis. The initiative is aimed at raising awareness and prompting patient-provider conversations. See our latest analysis for Kiniksa Pharmaceuticals International. Despite a mild 1 day share price return of negative 0.53% and a 7 day share price return of negative 3.56%, Kiniksa’s 90 day share price...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Is It Too Late To Reassess Palantir Technologies (PLTR) After The Recent Share Price Slide

If you are wondering whether Palantir Technologies at around US$128.06 is still priced for excitement or already ahead of itself, the starting point is to ask what you are actually paying for. The stock has seen a 13.7% decline over the last 7 days and a 16.6% decline over the last 30 days, even though the 1 year return sits at 44.6% and the 3 year return is very large. Recent coverage has focused on Palantir's role in data analytics and software platforms used by government and commercial...
NYSE:FIG
NYSE:FIGSoftware

Figma (FIG) Is Down 14.6% After AI Moat Concerns Emerge Despite Strong FY25 Growth - Has The Bull Case Changed?

Figma recently reported full-year 2025 revenue growth of 41% with solid free cash flow, while guiding 2026 growth to around 30% and remaining unprofitable. At the same time, investors are increasingly focused on how generative AI and intensified competition from Adobe could weaken Figma’s competitive position, even as user adoption remains strong. We’ll now examine how investor concerns about AI eroding Figma’s moat may influence the company’s existing investment narrative and risk...
TSX:AGI
TSX:AGIMetals and Mining

Assessing Alamos Gold (TSX:AGI) Valuation After Strong Earnings Growth And Island Gold Phase 3+ Expansion

Alamos Gold (TSX:AGI) is back in focus after reporting a 71.6% increase in earnings per share and 34.3% revenue growth, supported by the Phase 3+ Expansion at the Island Gold mine and solid profitability. See our latest analysis for Alamos Gold. The recent earnings surprise appears to be feeding into sentiment, with the CA$67.1 share price supported by a 27.3% year to date share price return and a very large 5 year total shareholder return. This points to momentum that has been building...